Board of Directors


John D. Diekman, Ph.D., Chairman of the Board

Founding Partner, 5AM Ventures

John D. Diekman, Ph.D. is a Founding Partner of 5AM Ventures. Previously Dr. Diekman was Chairman and CEO of Affymetrix, and Chairman and Managing Director of Affymax. Dr. Diekman currently serves as Chairman of IDEAYA as well as on the Boards of Igenica and Wildcat. He is a Charter Trustee of Princeton University and a former Trustee of the California Institute of Technology and of the Scripps Research Institute, where he served as Chairman. He serves on the Schaeffer Center for Health Policy and Economics Advisory Board at the University of Southern California. He is an Honorary Officer of the Order of Australia. Dr. Diekman received a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. Dr. Diekman holds an Honorary Degree of Doctor of Laws from Monash University.


Timothy Shannon, M.D., Board Member

General Partner, Canaan Partners

Timothy Shannon, M.D., is a General Partner at Canaan Partners where he focuses on early stage biopharmaceutical companies. He is chairman of the board of Arvinas and Spyryx Therapeutics and is a director at NextCure, Vivace, and CytomX (CTMX, IPO 2015). Prior successful companies include Civitas Theraputics (acquired by Acorda) and Novira Therapeutics (acquired by J&J). Dr. Shannon previously was president and chief executive officer of CuraGen, a publically traded biopharmaceutical company.  CuraGen merged with Celldex Therapeutics in 2009 where Dr. Shannon served on the board. Prior to that he was senior vice president of global medical development for Bayer’s Pharmaceutical Business Group. Dr. Shannon began his career as an assistant professor of pulmonary and critical care medicine at Yale University School of Medicine, received his M.D. from the University of Connecticut, and his B.A. from Amherst College.


Terry Rosen, Ph.D., Board Member

Chief Executive Officer, Arcus Biosciences

Terry Rosen, Ph.D. is currently the CEO of Arcus Biosciences.  He previously served as CEO of Flexus Biosciences, which was acquired by BMS in 2015.  Prior to co-founding Flexus in October of 2013, Terry served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004.  Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry.  He has also held scientific and management positions at Pfizer and Abbott Laboratories. Terry serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology and Biology and Biological Engineering Chair’s Council and the California Life Sciences Association Board. He holds a B.S. in Chemistry from the University of Michigan and a Ph.D. in Organic Chemistry from the University of California, Berkeley.


Jeffrey Stein, Ph.D., Board Member

Chief Executive Officer, Cidara Therapeutics

Jeffrey Stein, Ph.D., has been the President and Chief Executive Officer of Cidara Therapeutics since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein was also the founding Chairman and President of the Antibiotics Working Group. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at UCSD.


Yujiro S. Hata, Board Member

Co-Founder and CEO, IDEAYA Biosciences


Peter Worland, Ph.D., Board Observer

Corporate Vice President, Integrative Research Development, Celgene

Peter Worland, Ph.D., is currently Corporate Vice President of Integrative Research Development at Celgene where he identifies collaborations (academic and corporate) that extend the reach of Celgene’s internal research programs and development pipeline. He has been integral to creating numerous collaborations over the last 9 years at Celgene and is continually working to maximize the value of existing partnerships and identify new potential partnerships complementing the Celgene strategic plan.  Prior to this, Peter had responsibility for Experimental Therapeutics within the Discovery group. Prior to joining Celgene, Peter ran the Discovery Oncology effort at Millennium, led Discovery programs at Pharmacia and managed academic collaborations at the European Institute of Oncology, Milan and built the Pharmacology group and led Discovery programs at Mitotix in Cambridge, MA. After completing his Ph.D. in the Clinical Pharmacology Unit, Department of Medicine, University of Melbourne, Australia, Peter worked as a Visiting Scientist at the NCI for a number of years before entering industry. 


Edward Hu, Ph.D., Board Observer

Founding Partner, WuXi Healthcare Ventures; CFO and CIO, WuXi AppTec 

Edward Hu, Ph.D., M.B.A. is currently CFO and CIO at WuXi AppTec, and Partner at WuXi Healthcare Ventures. Mr. Hu manages the company’s finance, investments, mergers and acquisitions, joint ventures, and new business and capability building. In addition, Mr. Hu oversees WuXi Healthcare Ventures’ investment activities and portfolio management. Mr. Hu previously served as WuXi’s COO and CFO until April 2014. Prior to joining WuXi in August 2007, Mr. Hu was SVP and COO at Tanox, responsible for operations, finance, IT, project management and strategic planning, and managed the acquisition of Tanox by Genentech in 2007. He also held positions at Merck & Co., Inc. as a Senior Financial Analyst and later in Business and Financial Planning at Biogen, Inc., where he managed the business planning of Biogen’s R&D and clinical operations organizations, and provided project planning and analysis support to key drug development project teams. Mr. Hu completed his Ph.D. work, all but dissertation, in Biophysics and Biochemistry at Carnegie Mellon University, where he also received his M.B.A. 


Hannah H. Chang, M.D., Ph.D.  Board Observer

Associate, 5AM Ventures

Hannah H. Chang, M.D., Ph.D. is an Associate at 5AM Ventures. She currently serves as an Observer on the Boards of Biodesy, Cleave Biosciences, Crinetics Pharmaceuticals and IDEAYA Biosciences. Previously, she was a Project Leader at The Boston Consulting Group where she was a member of the Health Care and Strategy Practices. Before joining 5AM, Dr. Chang was an M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program and an Ashford Fellow. She completed an internship in Internal Medicine at the Beth Israel Deaconess Medical Center and pursued residency in Ophthalmology at the Massachusetts Eye and Ear Infirmary. Her Ph.D. work at Harvard focused on the dynamics of mammalian stem cell differentiation and was published in Nature. She holds a B.A. in Chemistry from Princeton University, a Ph.D. in Biophysics from Harvard University and an M.D. from Harvard Medical School. Dr. Chang is based in the Menlo Park, CA office.